InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（2 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
2
T+90 胜率
100%
T+90 平均收益
+177.4%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Explore the full record of transactions filed by Morabito Christopher, Directeur Médical. Officer active across 2 companies, notably Fulcrum Therapeutics, Inc.. In total, 6 disclosures have been recorded. Split: 1 buy · 2 sells. Total volume traded: €111k. History available since 28 June 2021. The latest transaction was disclosed on 1 April 2024 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Morabito Christopher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
10,000 股@ US$3.8720.7% 占其流量Common StockSEC:0001104659-24-043092:0
800 股@ US$3.871.6% 占其流量Common StockSEC:0001104659-24-008327:0
800 股@ US$11.0154.7% 占其流量Common StockSEC:0001104659-24-008327:1
9,200 股@ US$3.8718.8% 占其流量Common StockSEC:0001104659-24-008327:2
9,200 股@ US$11.14754.2% 占其流量Common StockSEC:0001104659-24-008327:3
1,100 股@ US$9.16100.0% 占其流量Common StockSEC:0000899243-21-026557:0
标准退出：2021年9月26日 (T+90)
6 条申报中的 6 条
About Morabito Christopher
Christopher Morabito is the Chief Medical Officer at Fulcrum Therapeutics, Inc. In this role, he is responsible for leading the company's clinical initiatives and medical research. With a strong background in the biopharmaceutical sector, Christopher plays a key role in developing innovative therapies. His expertise is essential to ensure regulatory compliance and the effectiveness of clinical trials at Fulcrum.
